Amphastar Pharmaceuticals AMPH Pharmaceutical Products — Net Income Loss

Similar metrics at other companies

ANABBiopharma Company — Net Income Loss

-$50.48M-7.0%

SNDXBiopharmaceutical Cancer Therapeutics — Net Income Loss

-$42.67M+49.7%

VRTXPharmaceuticals — income (loss)

$1.03B+59.6%

OPKPharmaceutical — Operating Income

-$29.68M+14.6%

PTCTLife Science — Net Income Loss

-$2.81M-100%

BLCOPharmaceuticals — Operating Income (Loss)

$66M+500%

Questions, answered.

What is Amphastar Pharmaceuticals's pharmaceutical products — net income loss?

Amphastar Pharmaceuticals (AMPH) reported pharmaceutical products — net income loss of $6.42M in Q1 2026.

How has Amphastar Pharmaceuticals's pharmaceutical products — net income loss changed year-over-year?

Amphastar Pharmaceuticals's pharmaceutical products — net income loss decreased by 74.6% year-over-year, from $25.29M to $6.42M.

What does pharmaceutical products — net income loss mean?

This metric represents the final bottom-line profitability of the pharmaceutical products segment after accounting for all revenues, operating expenses, interest, taxes, and other non-operating items. It serves as the primary indicator of the segment's financial health and its ability to generate value for the company. Investors use this to assess the core earnings power of the segment's product portfolio.